Poor clinical trial results for the drug have lowered Novartis’ stock value
This was reported a few days after the company announced poor and long-awaited Phase III clinical trial results for a heart disease drug, which were also worse than expected. Read more The district court will announce the decision in the case of Irma Gajauskaitė regarding riots and incitement on October 22 Novartis shares in Zurich…
